WFMPM
SRPT icon

Woodley Farra Manion Portfolio Management’s Sarepta Therapeutics SRPT Stock Holding History

Woodley Farra Manion Portfolio Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-304
Closed -$49K – 349
2020
Q2 		$49K Hold
304
– – 0.01% 168
2020
Q1 		$30K Hold
304
– – ﹤0.01% 198
2019
Q4 		$39K Buy
+304
New +$30.7K ﹤0.01% 197

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Woodley Farra Manion Portfolio Management's SRPT Position: Q3 2020 in Review

Woodley Farra Manion Portfolio Management sold out of Sarepta Therapeutics (SRPT) in Q3 2020, closing a stake of 304 shares — an estimated $49K sold.

Woodley Farra Manion Portfolio Management first reported a position in SRPT in Q4 2019 and held it in 3 quarters. The position peaked at $49K in Q2 2020. 404 funds tracked by Wall St. Rank hold SRPT as of Q3 2020.

  • Woodley Farra Manion Portfolio Management reported no remaining Sarepta Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Woodley Farra Manion Portfolio Management sold 304 Sarepta Therapeutics shares in Q3 2020, an estimated $49K.
  • Woodley Farra Manion Portfolio Management first reported a position in Sarepta Therapeutics in Q4 2019 and held it in 3 quarters.
  • Woodley Farra Manion Portfolio Management's Sarepta Therapeutics position peaked at $49K in Q2 2020.
  • 404 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2020.

Based on Woodley Farra Manion Portfolio Management's 13F filing for Q3 2020, filed 5 Nov 2020.